Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or hydrochlorothiazide. Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydrochlorothiazide. Patients taking losartan should have their renal function and potassium levels monitored. Losartan was granted FDA approval on 14 April 1995.
Losartan is indicated to treat hypertension in patients older than 6 years, reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage), and to treat diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and hypertension. Losartan with hydrochlorothiazide is indicated to treat hypertension and to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage).
Emory University, Atlanta, Georgia, United States
Northwestern Univ-Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
University of Washington, Seattle, Washington, United States
Clinical Unit, Reliance Life Sciences Pvt. Ltd., Mumbai, Maharashtra, India
The University of Texas Health Science Center at Houston, Houston, Texas, United States
University of Kansas Medical Center, Kansas City, Kansas, United States
University of Electronic Science and Technology of China, Chengdu, Sichuan, China
University of British Columbia, Kelowna, British Columbia, Canada
UAB Center for Exercise Medicine, Birmingham, Alabama, United States
Translational Research Institute, Orlando, Florida, United States
Helsinki University Central Hospital, Helsinki, Finland
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.